Company Announcements

NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, December 20, 2021.

The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market^® (Nasdaq^®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).

The following 129 securities will be added to the Index:

Exchange	Ticker	Company
Nasdaq	BTX	Brooklyn ImmunoTherapeutics, Inc.
Nasdaq	LXRX	Lexicon Pharmaceuticals, Inc.
Nasdaq	CRIS	Curis, Inc.
Nasdaq	HBIO	Harvard Bioscience, Inc.
Nasdaq	EYPT	EyePoint Pharmaceuticals, Inc.
Nasdaq	MTEM	Molecular Templates, Inc.
Nasdaq	VIRX	Viracta Therapeutics, Inc.
Nasdaq	AVXL	Anavex Life Sciences Corp.
Nasdaq	INFI	Infinity Pharmaceuticals, Inc.
Nasdaq	HROW	Harrow Health, Inc.
Nasdaq	TNXP	Tonix Pharmaceuticals Holding Corp.
Nasdaq	CMRX	Chimerix, Inc.
Nasdaq	ADMA	ADMA Biologics Inc
Nasdaq	SESN	Sesen Bio, Inc.
Nasdaq	CLSD	Clearside Biomedical, Inc.
Nasdaq	PRQR	ProQR Therapeutics N.V.
Nasdaq	ALPN	Alpine Immune Sciences, Inc.
Nasdaq	ACRS	Aclaris Therapeutics, Inc.
Nasdaq	NVCR	NovoCure Limited
Nasdaq	MRUS	Merus N.V.
Nasdaq	OCX	Oncocyte Corporation
Nasdaq	CRVS	Corvus Pharmaceuticals, Inc.
Nasdaq	LPTX	Leap Therapeutics, Inc.
Nasdaq	OBSV	ObsEva SA
Nasdaq	MBIO	Mustang Bio, Inc.
Nasdaq	OPTN	OptiNose, Inc.
Nasdaq	SLDB	Solid Biosciences Inc.
Nasdaq	NRXP	NRX Pharmaceuticals, Inc.
Nasdaq	EOLS	Evolus, Inc.
Nasdaq	COGT	Cogent Biosciences, Inc.
Nasdaq	MREO	Mereo BioPharma Group plc
Nasdaq	AQST	Aquestive Therapeutics, Inc.
Nasdaq	EVLO	Evelo Biosciences, Inc.
Nasdaq	VRCA	Verrica Pharmaceuticals Inc.
Nasdaq	GRTS	Gritstone bio, Inc.
Nasdaq	INBX	Inhibrx, Inc.
Nasdaq	BCYC	Bicycle Therapeutics plc
Nasdaq	CDAK	Codiak BioSciences, Inc.
Nasdaq	MIRM	Mirum Pharmaceuticals, Inc.
Nasdaq	IMPL	Impel NeuroPharma, Inc.
Nasdaq	MORF	Morphic Holding, Inc.
Nasdaq	OYST	Oyster Point Pharma, Inc.
Nasdaq	ETNB	89bio, Inc.
Nasdaq	PHAT	Phathom Pharmaceuticals, Inc.
Nasdaq	FDMT	4D Molecular Therapeutics, Inc.
Nasdaq	CVAC	CureVac N.V.
Nasdaq	HRMY	Harmony Biosciences Holdings, Inc.
Nasdaq	VTRS	Viatris Inc.
Nasdaq	QSI	Quantum-Si Incorporated
Nasdaq	PMVP	PMV Pharmaceuticals, Inc.
Nasdaq	KYMR	Kymera Therapeutics, Inc.
Nasdaq	NAUT	Nautilus Biotechnology, Inc.
Nasdaq	DYN	Dyne Therapeutics, Inc.
Nasdaq	CCCC	C4 Therapeutics, Inc.
Nasdaq	HUMA	Humacyte, Inc.
Nasdaq	ATHA	Athira Pharma, Inc.
Nasdaq	LABP	Landos Biopharma, Inc.
Nasdaq	TSHA	Taysha Gene Therapies, Inc.
Nasdaq	ONCR	Oncorus, Inc.
Nasdaq	PRAX	Praxis Precision Medicines, Inc.
Nasdaq	CMPS	COMPASS Pathways Plc
Nasdaq	PRLD	Prelude Therapeutics Incorporated
Nasdaq	BOLT	Bolt Biotherapeutics, Inc.
Nasdaq	ABCM	Abcam plc
Nasdaq	STTK	Shattuck Labs, Inc.
Nasdaq	KRON	Kronos Bio, Inc.
Nasdaq	ALGS	Aligos Therapeutics, Inc.
Nasdaq	AVIR	Atea Pharmaceuticals, Inc.
Nasdaq	OLMA	Olema Pharmaceuticals, Inc.
Nasdaq	SBTX	Silverback Therapeutics, Inc.
Nasdaq	MRVI	Maravai LifeSciences Holdings, Inc.
Nasdaq	BCAB	BioAtla, Inc.
Nasdaq	GRCL	Gracell Biotechnologies Inc.
Nasdaq	KNTE	Kinnate Biopharma Inc.
Nasdaq	SEER	Seer, Inc.
Nasdaq	ME	23andMe Holding Co.
Nasdaq	KMPH	KemPharm, Inc.
Nasdaq	BVS	Bioventus Inc.
Nasdaq	SNSE	Sensei Biotherapeutics, Inc.
Nasdaq	SABS	SAB Biotherapeutics, Inc.
Nasdaq	VOR	Vor Biopharma Inc.
Nasdaq	ABCL	AbCellera Biologics Inc.
Nasdaq	CGEM	Cullinan Oncology, Inc.
Nasdaq	DBTX	Decibel Therapeutics, Inc.
Nasdaq	CNTB	Connect Biopharma Holdings Limited
Nasdaq	SANA	Sana Biotechnology, Inc.
Nasdaq	ACHL	Achilles Therapeutics plc
Nasdaq	IKNA	Ikena Oncology, Inc.
Nasdaq	TERN	Terns Pharmaceuticals, Inc.
Nasdaq	EWTX	Edgewise Therapeutics, Inc.
Nasdaq	RXRX	Recursion Pharmaceuticals, Inc.
Nasdaq	RXDX	Prometheus Biosciences, Inc.
Nasdaq	TIL	Instil Bio, Inc.
Nasdaq	DSGN	Design Therapeutics, Inc.
Nasdaq	BMEA	Biomea Fusion, Inc.
Nasdaq	RAIN	Rain Therapeutics Inc.
Nasdaq	ATAI	ATAI Life Sciences N.V.
Nasdaq	CADL	Candel Therapeutics, Inc.
Nasdaq	HOWL	Werewolf Therapeutics, Inc.
Nasdaq	TALS	Talaris Therapeutics, Inc.
Nasdaq	CYT	Cyteir Therapeutics, Inc.
Nasdaq	OMIC	Singular Genomics Systems, Inc.
Nasdaq	DNAY	Codex DNA, Inc.
Nasdaq	CNTA	Centessa Pharmaceuticals plc
Nasdaq	IMGO	Imago BioSciences, Inc.
Nasdaq	IPSC	Century Therapeutics, Inc.
Nasdaq	SERA	Sera Prognostics, Inc.
Nasdaq	RANI	Rani Therapeutics Holdings, Inc.
Nasdaq	VERV	Verve Therapeutics, Inc.
Nasdaq	DAWN	Day One Biopharmaceuticals, Inc.
Nasdaq	JANX	Janux Therapeutics, Inc.
Nasdaq	TKNO	Alpha Teknova, Inc.
Nasdaq	GLUE	Monte Rosa Therapeutics, Inc.
Nasdaq	RPID	Rapid Micro Biosystems, Inc.
Nasdaq	AVTE	Aerovate Therapeutics, Inc.
Nasdaq	ERAS	Erasca, Inc.
Nasdaq	TNYA	Tenaya Therapeutics, Inc.
Nasdaq	ICVX	Icosavax, Inc.
Nasdaq	IMRX	Immuneering Corporation
Nasdaq	RLYB	Rallybio Corporation
Nasdaq	GRPH	Graphite Bio, Inc.
Nasdaq	ABOS	Acumen Pharmaceuticals, Inc.
Nasdaq	LYEL	Lyell Immunopharma, Inc.
Nasdaq	ABSI	Absci Corporation
Nasdaq	NUVL	Nuvalent, Inc.
Nasdaq	OMGA	Omega Therapeutics, Inc.
Nasdaq	CRBU	Caribou Biosciences, Inc.
Nasdaq	MXCT	MaxCyte, Inc.
Nasdaq	BLU	BELLUS Health Inc.

As a result of the reconstitution, the following 21 securities will be removed from the Index:

Exchange	Ticker	Company
Nasdaq	MNOV	MediciNova, Inc.
Nasdaq	ASMB	Assembly Biosciences, Inc.
Nasdaq	CNCE	Concert Pharmaceuticals, Inc.
Nasdaq	ARDX	Ardelyx, Inc.
Nasdaq	CALA	Calithera Biosciences, Inc.
Nasdaq	XBIT	XBiotech Inc.
Nasdaq	KALA	Kala Pharmaceuticals, Inc.
Nasdaq	VYGR	Voyager Therapeutics, Inc.
Nasdaq	ODT	Odonate Therapeutics, Inc.
Nasdaq	VYNE	VYNE Therapeutics Inc.
Nasdaq	UBX	Unity Biotechnology, Inc.
Nasdaq	OSMT	Osmotica Pharmaceuticals plc
Nasdaq	ORTX	Orchard Therapeutics plc
Nasdaq	KLDO	Kaleido Biosciences, Inc.
Nasdaq	BCEL	Atreca, Inc.
Nasdaq	APRE	Aprea Therapeutics, Inc.
Nasdaq	FUSN	Fusion Pharmaceuticals Inc.
Nasdaq	INZY	Inozyme Pharma, Inc.
Nasdaq	TSVTV	2seventy bio, Inc.
Nasdaq	ANIP	ANI Pharmaceuticals, Inc.
Nasdaq	DRNA	Dicerna Pharmaceuticals, Inc.

About Nasdaq
Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software, and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com.

Media Contact
Emily Pan
emily.pan@nasdaq.com
+1 (646) 637-3964

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither The NASDAQ OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq’s proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

- NDAQG -